◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › A › AUTL

Autolus Therapeutics Ltd (AUTL) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-27

Autolus Therapeutics Ltd (AUTL) operates in the BIOTECHNOLOGY industry and is headquartered in London, United Kingdom with about 752 employees. Its market capitalization is roughly $377 million. In the fiscal year ended 2025-12-31, AUTL reported $76M in revenue and ($288M) in net income.

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally.

Interactive charts & full statements → Open the AUTL valuation workbench →

AUTL Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2018-09-30	2017-12-31	2016-12-31	2015-12-31
Total Revenue	$117M	$76M	$10M	$2M	$6M	$2M	$2M	$3M	$1M	$1M	$2M	$1M	$0M
Gross Profit	$18M	($21M)	($131M)	$2M	$6M	$2M	($133M)	($103M)	($47M)	($47M)	$1M	$1M	$0M
Gross Margin %	15.7%	-27.8%	-1293.5%	100.0%	100.0%	100.0%	-7765.2%	-3525.1%	-4520.4%	-4520.4%	40.4%	60.6%	100.0%
Operating Income (EBIT)	($247M)	($281M)	($241M)	($180M)	($143M)	($140M)	($303M)	($248M)	($58M)	($58M)	($23M)	($14M)	($8M)
Operating Margin %	-210.8%	-372.4%	-2385.6%	-10583.1%	-2307.0%	-9314.8%	-17675.4%	-8513.8%	-5503.7%	-5503.7%	-1383.2%	-1186.1%	-8613.8%
Net Income	($280M)	($288M)	($221M)	($208M)	($149M)	($142M)	($142M)	($124M)	($31M)	($31M)	($20M)	($13M)	($7M)
Net Margin %	-238.6%	-381.4%	-2180.5%	-12272.3%	-2402.9%	-9429.1%	-8285.4%	-4258.9%	-2976.5%	-2976.5%	-1165.2%	-1035.5%	-7931.1%
EBITDA	($221M)	($250M)	($233M)	($157M)	($132M)	($132M)	($163M)	($137M)	($50M)	($35M)	($22M)	($14M)	($4M)
Earnings Per Share (EPS)	$-1.05	$-1.08	$-0.86	$-1.20	$-1.57	$-1.97	$-2.76	$-2.88	$-0.99	$-0.99	$-1.43	$-0.91	$-0.54
Shares Outstanding (M)	266M	266M	255M	174M	95M	72M	52M	43M	32M	32M	14M	14M	14M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AUTL Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$46M	$26M	$24M	$21M	$21M	$9M	$0M	$0M
Gross Profit	$25M	$2M	($1M)	($7M)	($4M)	($9M)	($138M)	($1M)
Gross Margin %	55.2%	6.3%	-4.3%	-35.1%	-16.8%	-99.9%	-476810.3%	—
Operating Income (EBIT)	($44M)	($60M)	($72M)	($72M)	($61M)	($65M)	($241M)	($69M)
Operating Margin %	-96.0%	-227.0%	-298.3%	-337.9%	-292.6%	-726.3%	-832503.4%	—
Net Income	($39M)	($72M)	($90M)	($79M)	($48M)	($70M)	($28M)	($82M)
Net Margin %	-85.6%	-273.1%	-371.9%	-373.3%	-229.0%	-781.1%	-95193.1%	—
EBITDA	($34M)	($57M)	($66M)	($65M)	($43M)	($56M)	($74M)	($66M)
Earnings Per Share (EPS)	$-0.15	$-0.27	$-0.34	$-0.30	$-0.18	$-0.26	$-0.10	$-0.31
Shares Outstanding (M)	266M	266M	266M	266M	266M	266M	266M	266M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AUTL Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2018-09-30	2017-12-31	2016-12-31	2015-12-31
Cash from Operations (CFO)	($226M)	($284M)	($206M)	($146M)	($112M)	($118M)	($118M)	($101M)	($26M)	($26M)	($16M)	($10M)	($3M)
Capital Expenditures (CapEx)	$43M	$27M	$35M	$11M	$11M	$9M	$15M	$19M	$9M	$9M	$3M	$2M	$1M
Free Cash Flow (FCF)	($268M)	($311M)	($241M)	($157M)	($123M)	($127M)	($132M)	($120M)	($35M)	($35M)	($19M)	($12M)	($4M)
FCF Margin %	-228.8%	-411.2%	-2382.3%	-9221.0%	-1988.2%	-8408.6%	-7722.4%	-4131.8%	-3311.7%	-3311.7%	-1136.2%	-965.7%	-4343.2%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AUTL Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($25M)	($65M)	($67M)	($68M)	($73M)	($76M)	($38M)	($77M)
Capital Expenditures (CapEx)	$1M	$3M	$24M	$16M	$7M	$8M	$24M	$10M
Free Cash Flow (FCF)	($26M)	($68M)	($91M)	($83M)	($80M)	($84M)	($62M)	($86M)
FCF Margin %	-56.9%	-259.4%	-375.6%	-393.6%	-382.6%	-933.1%	-213069.0%	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AUTL Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2018-09-30	2017-12-31	2016-12-31	2015-12-31
Total Assets	$493M	$589M	$783M	$375M	$490M	$406M	$294M	$304M	$218M	$218M	$149M	$34M	$23M
Cash & Cash Equivalents	$171M	$104M	$227M	$240M	$382M	$310M	$154M	$211M	$189M	$189M	$137M	$28M	$10M
Total Liabilities	$418M	$411M	$355M	$264M	$192M	$92M	$84M	$49M	$13M	$13M	$6M	$3M	$2M
Total Debt (Short + Long-Term)	$6M	$15M	$3M	$5M	$5M	$4M	$4M	$3M	$0M	$0M	$0M	$0M	$0M
Total Shareholders' Equity	$75M	$178M	$427M	$111M	$299M	$313M	$210M	$255M	$205M	$205M	$143M	$31M	$21M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive AUTL viewer.

Other Companies in BIOTECHNOLOGY

ZURA · Zura Bio Limited Class A Ordinary Shares — $389 million
TECX · Tectonic Therapeutic, Inc. — $387 million
RLMD · Relmada Therapeutics Inc — $382 million
MPLT · MapLight Therapeutics, Inc. Common Stock — $378 million
AGMB · AgomAb Therapeutics NV American Depositary Shares — $369 million
CTNM · Contineum Therapeutics, Inc. Class A Common Stock — $365 million
FENC · Fennec Pharmaceuticals Inc — $359 million
KYTX · Kyverna Therapeutics, Inc. Common Stock — $351 million

← AUSTENG All “A” companies AUTME →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.